The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gene Therapy in CNS Disorder Market Research Report 2025
Synopsis
Gene therapy entails the specific transfer of genetic information into affected cells and tissues in order to restore function in diseased areas.
Global Gene Therapy in CNS Disorder market is projected to reach US$ 1388.6 million in 2029, increasing from US$ 514 million in 2022, with the CAGR of 15.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gene Therapy in CNS Disorder market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gene Therapy in CNS Disorder market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Voyager Therapeutics
Spark Therapeutics
Novartis AG
Bluebird Bio Inc.
Biogen
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Segment by Application
Alzheimer's Disease
Huntington's Disease
Parkinson's Disease
Batten Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gene Therapy in CNS Disorder report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Gene therapy entails the specific transfer of genetic information into affected cells and tissues in order to restore function in diseased areas.
Global Gene Therapy in CNS Disorder market is projected to reach US$ 1388.6 million in 2029, increasing from US$ 514 million in 2022, with the CAGR of 15.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gene Therapy in CNS Disorder market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Gene Therapy in CNS Disorder market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Voyager Therapeutics
Spark Therapeutics
Novartis AG
Bluebird Bio Inc.
Biogen
Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Segment by Application
Alzheimer's Disease
Huntington's Disease
Parkinson's Disease
Batten Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Gene Therapy in CNS Disorder report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy in CNS Disorder Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Viral Gene Therapy
1.2.3 Non-viral Gene Therapy
1.3 Market by Application
1.3.1 Global Gene Therapy in CNS Disorder Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Alzheimer's Disease
1.3.3 Huntington's Disease
1.3.4 Parkinson's Disease
1.3.5 Batten Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy in CNS Disorder Market Perspective (2018-2029)
2.2 Gene Therapy in CNS Disorder Growth Trends by Region
2.2.1 Global Gene Therapy in CNS Disorder Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Gene Therapy in CNS Disorder Historic Market Size by Region (2018-2023)
2.2.3 Gene Therapy in CNS Disorder Forecasted Market Size by Region (2024-2029)
2.3 Gene Therapy in CNS Disorder Market Dynamics
2.3.1 Gene Therapy in CNS Disorder Industry Trends
2.3.2 Gene Therapy in CNS Disorder Market Drivers
2.3.3 Gene Therapy in CNS Disorder Market Challenges
2.3.4 Gene Therapy in CNS Disorder Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy in CNS Disorder Players by Revenue
3.1.1 Global Top Gene Therapy in CNS Disorder Players by Revenue (2018-2023)
3.1.2 Global Gene Therapy in CNS Disorder Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy in CNS Disorder Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gene Therapy in CNS Disorder Revenue
3.4 Global Gene Therapy in CNS Disorder Market Concentration Ratio
3.4.1 Global Gene Therapy in CNS Disorder Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy in CNS Disorder Revenue in 2022
3.5 Gene Therapy in CNS Disorder Key Players Head office and Area Served
3.6 Key Players Gene Therapy in CNS Disorder Product Solution and Service
3.7 Date of Enter into Gene Therapy in CNS Disorder Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy in CNS Disorder Breakdown Data by Type
4.1 Global Gene Therapy in CNS Disorder Historic Market Size by Type (2018-2023)
4.2 Global Gene Therapy in CNS Disorder Forecasted Market Size by Type (2024-2029)
5 Gene Therapy in CNS Disorder Breakdown Data by Application
5.1 Global Gene Therapy in CNS Disorder Historic Market Size by Application (2018-2023)
5.2 Global Gene Therapy in CNS Disorder Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Gene Therapy in CNS Disorder Market Size (2018-2029)
6.2 North America Gene Therapy in CNS Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Gene Therapy in CNS Disorder Market Size by Country (2018-2023)
6.4 North America Gene Therapy in CNS Disorder Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy in CNS Disorder Market Size (2018-2029)
7.2 Europe Gene Therapy in CNS Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Gene Therapy in CNS Disorder Market Size by Country (2018-2023)
7.4 Europe Gene Therapy in CNS Disorder Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy in CNS Disorder Market Size (2018-2029)
8.2 Asia-Pacific Gene Therapy in CNS Disorder Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Gene Therapy in CNS Disorder Market Size by Region (2018-2023)
8.4 Asia-Pacific Gene Therapy in CNS Disorder Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy in CNS Disorder Market Size (2018-2029)
9.2 Latin America Gene Therapy in CNS Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Gene Therapy in CNS Disorder Market Size by Country (2018-2023)
9.4 Latin America Gene Therapy in CNS Disorder Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy in CNS Disorder Market Size (2018-2029)
10.2 Middle East & Africa Gene Therapy in CNS Disorder Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Gene Therapy in CNS Disorder Market Size by Country (2018-2023)
10.4 Middle East & Africa Gene Therapy in CNS Disorder Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Detail
11.1.2 Voyager Therapeutics Business Overview
11.1.3 Voyager Therapeutics Gene Therapy in CNS Disorder Introduction
11.1.4 Voyager Therapeutics Revenue in Gene Therapy in CNS Disorder Business (2018-2023)
11.1.5 Voyager Therapeutics Recent Development
11.2 Spark Therapeutics
11.2.1 Spark Therapeutics Company Detail
11.2.2 Spark Therapeutics Business Overview
11.2.3 Spark Therapeutics Gene Therapy in CNS Disorder Introduction
11.2.4 Spark Therapeutics Revenue in Gene Therapy in CNS Disorder Business (2018-2023)
11.2.5 Spark Therapeutics Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Gene Therapy in CNS Disorder Introduction
11.3.4 Novartis AG Revenue in Gene Therapy in CNS Disorder Business (2018-2023)
11.3.5 Novartis AG Recent Development
11.4 Bluebird Bio Inc.
11.4.1 Bluebird Bio Inc. Company Detail
11.4.2 Bluebird Bio Inc. Business Overview
11.4.3 Bluebird Bio Inc. Gene Therapy in CNS Disorder Introduction
11.4.4 Bluebird Bio Inc. Revenue in Gene Therapy in CNS Disorder Business (2018-2023)
11.4.5 Bluebird Bio Inc. Recent Development
11.5 Biogen
11.5.1 Biogen Company Detail
11.5.2 Biogen Business Overview
11.5.3 Biogen Gene Therapy in CNS Disorder Introduction
11.5.4 Biogen Revenue in Gene Therapy in CNS Disorder Business (2018-2023)
11.5.5 Biogen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
